# Superiority of Newly Developed Over Basic Echinacea Formulations for the Treatment of Respiratory Tract Infections

> **NCT03812900** · PHASE2,PHASE3 · COMPLETED · sponsor: **A. Vogel AG** · enrollment: 246 (actual)

## Conditions studied

- Respiratory Tract Infections

## Interventions

- **DRUG:** Echinacea purpurea alcoholic extract

## Key facts

- **NCT ID:** NCT03812900
- **Lead sponsor:** A. Vogel AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-27
- **Primary completion:** 2019-06-05
- **Final completion:** 2019-06-07
- **Target enrollment:** 246 (ACTUAL)
- **Last updated:** 2021-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03812900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03812900, "Superiority of Newly Developed Over Basic Echinacea Formulations for the Treatment of Respiratory Tract Infections". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03812900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*